Alterations in PGC1α expression levels are involved in colorectal cancer risk: a qualitative systematic review

Abstract

BackgroundColorectal cancer (CRC) is a major global public health problem and the second leading cause of cancer-related death. Mitochondrial dysfunction has long been suspected to be involved in this type of tumorigenesis, as supported by an accumulating body of research evidence. However, little is known about how mitochondrial alterations contribute to tumorigenesis. Mitochondrial biogenesis is a fundamental cellular process required to maintain functional mitochondria and as an adaptive mechanism in response to changing energy requirements. Mitochondrial biogenesis is regulated by peroxisome proliferator-activated receptor gamma coactivator 1-α (PPARGC1A or PGC1α). In this paper, we report a systematic review to summarize current evidence on the role of PGC1α in the initiation and progression of CRC. The aim is to provide a basis for more comprehensive research.MethodsThe literature search, data extraction and quality assessment were performed according to the document Guidance on the Conduct of Narrative Synthesis in Systematic Reviews and the PRISMA declaration.ResultsThe studies included in this review aimed to evaluate whether increased or decreased PGC1α expression affects the development of CRC. Each article proposes a possible molecular mechanism of action and we create two concept maps.ConclusionOur systematic review indicates that altered expression of PGC1α modifies CRC risk. Most studies showed that overexpression of this gene increases CRC risk, while some studies indicated that lower than normal expression levels could increase CRC risk. Thus, various authors propose PGC1α as a good candidate molecular target for cancer therapy. Reducing expression of this gene could help to reduce risk or progression of CRC. Electronic supplementary materialThe online version of this article (10.1186/s12885-017-3725-3) contains supplementary material, which is available to authorized users.

p53 Affects PGC1α Stability Through AKT/GSK-3β to Enhance Cisplatin Sensitivity in Non-Small Cell Lung Cancer

“…In our experiments, PGC1α knockdown reduced the ATP content and the MMP in H1299 cells. This is consistent with the study of Alonso-Molero et al on colorectal cancer, which demonstrated that decreased levels of PGC1α reduced the MMP, thus reducing chemotherapy resistance ( 39 ). A study by Do et al using breast cancer MCF-7 cells found that decreased PGC1α expression rendered cells susceptible to oxidative stress damage by suppressing NRF2 ( 40 ).…”

GASVeM: A New Machine Learning Methodology for Multi-SNP Analysis of GWAS Data Based on Genetic Algorithms and Support Vector Machines

“…An article in a literature review article [54], aimed at evaluating whether increased or decreased peroxisome proliferator-activated receptor gamma coactivator 1-α (PPARGC1A or PGC1α) expression affects the development of colorectal cancer, found that an altered expression of PGC1α modifies colorectal cancer risk and mitochondrial biogenesis is regulated by PGC1α. According to this study, it seems plausible that the proposed algorithm found a relationship between the mitochondrial biogenesis pathway and colorectal cancer.…”

PGC-1α as a Biomarker of Physical Activity-Protective Effect on Colorectal Cancer

“…In addition, they emphasize the importance of the PGC family not only in functions related directly to the mitochondria but also in those indirect functions concerning cellular metabolic activity, emphasizing that the dysfunction in the PGC family can be the basis of pathologies such as cancer. This finding is reinforced by the works of Luo and colleagues (45) and Alonso-Molero and colleagues (48), which also highlight the importance of identification of various pathways regulated by the PGC-1 family as well as the different components that are influenced and affected by it.…”